These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 35462358)
1. Occupational Chronic Contact Dermatitis Successfully Treated with Dupilumab: A Case Series. Slodownik D; Levi A; Lapidoth M; Moshe S Dermatology; 2022; 238(6):1073-1075. PubMed ID: 35462358 [TBL] [Abstract][Full Text] [Related]
2. Blocking type 2 inflammation by dupilumab does not control classic (type 1-driven) allergic contact dermatitis in chronic hand eczema. Crepy MN; Nosbaum A; Bensefa-Colas L Contact Dermatitis; 2019 Aug; 81(2):145-147. PubMed ID: 30851059 [No Abstract] [Full Text] [Related]
3. The impact of dupilumab on patch testing and the prevalence of comorbid allergic contact dermatitis in recalcitrant atopic dermatitis: A retrospective chart review. Raffi J; Suresh R; Botto N; Murase JE J Am Acad Dermatol; 2020 Jan; 82(1):132-138. PubMed ID: 31562940 [TBL] [Abstract][Full Text] [Related]
4. Two differing presentations of periocular dermatitis as a side effect of dupilumab for atopic dermatitis. Yamane MLM; Belsito DV; Glass LRD Orbit; 2019 Oct; 38(5):390-394. PubMed ID: 30628518 [TBL] [Abstract][Full Text] [Related]
5. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163 [TBL] [Abstract][Full Text] [Related]
6. Allergic contact dermatitis to Compositae: A possible cause of dupilumab-associated facial and neck dermatitis in atopic dermatitis patients? Napolitano M; Fabbrocini G; Patruno C Contact Dermatitis; 2021 Oct; 85(4):473-474. PubMed ID: 33988858 [No Abstract] [Full Text] [Related]
7. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671 [TBL] [Abstract][Full Text] [Related]
8. A case series of dupilumab-treated allergic contact dermatitis patients. Goldminz AM; Scheinman PL Dermatol Ther; 2018 Nov; 31(6):e12701. PubMed ID: 30246906 [TBL] [Abstract][Full Text] [Related]
9. Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review. Hendricks AJ; Yosipovitch G; Shi VY J Dermatolog Treat; 2021 Feb; 32(1):19-28. PubMed ID: 31693426 [No Abstract] [Full Text] [Related]
10. Variable impact of dupilumab on patch testing results and allergic contact dermatitis in adults with atopic dermatitis. Stout M; Silverberg JI J Am Acad Dermatol; 2019 Jul; 81(1):157-162. PubMed ID: 30885752 [TBL] [Abstract][Full Text] [Related]
11. Dupilumab for the treatment of refractory allergic contact dermatitis from rubber/latex concomitant with atopic dermatitis. Koh YG; Park JW; Shin SH; Kim BJ; Yoo KH J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):e640-e643. PubMed ID: 35338674 [No Abstract] [Full Text] [Related]
12. Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study. Johansson EK; Ivert LU; Bradley B; Lundqvist M; Bradley M BMC Dermatol; 2020 Sep; 20(1):8. PubMed ID: 32962676 [TBL] [Abstract][Full Text] [Related]
13. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records. Wang C; Kraus CN; Patel KG; Ganesan AK; Grando SA Int J Dermatol; 2020 Feb; 59(2):253-256. PubMed ID: 31286499 [TBL] [Abstract][Full Text] [Related]
14. Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients. Guex-Crosier Y; Di-Lucca J; Häusermann P; Laffitte E; Saulite I; Schmid-Grendelmeier P; Schürch K; Thormann K; Simon D Swiss Med Wkly; 2021 Aug; 151():w30020. PubMed ID: 34495603 [TBL] [Abstract][Full Text] [Related]
15. The long-term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis-52 week results from the Dutch BioDay Registry. Voorberg AN; Romeijn GLE; de Bruin-Weller MS; Schuttelaar MLA Contact Dermatitis; 2022 Aug; 87(2):185-191. PubMed ID: 35279856 [TBL] [Abstract][Full Text] [Related]
16. Facial and neck erythema associated with dupilumab treatment: A systematic review. Jo CE; Finstad A; Georgakopoulos JR; Piguet V; Yeung J; Drucker AM J Am Acad Dermatol; 2021 May; 84(5):1339-1347. PubMed ID: 33428978 [TBL] [Abstract][Full Text] [Related]
17. Severe atopic dermatitis in a 21-month-old boy successfully treated with dupilumab. Mazzoni D; Lobo Y; Levitt D; Wheller L Pediatr Dermatol; 2022 Jul; 39(4):606-608. PubMed ID: 35575257 [TBL] [Abstract][Full Text] [Related]
18. Safety of dupilumab in a 5-month-old infant with severe atopic dermatitis. Havele SA; Khurana MC; McMahon P; Murthy AS; Perman MJ; Treat JR Pediatr Dermatol; 2022 Mar; 39(2):291-294. PubMed ID: 35434859 [TBL] [Abstract][Full Text] [Related]
19. Rapid response to dupilumab treatment in children with moderate-to-severe atopic dermatitis: A case series. Votto M; Delle Cave F; De Filippo M; Marseglia A; Marseglia GL; Brazzelli V; Licari A Pediatr Allergy Immunol; 2022 Jan; 33 Suppl 27(Suppl 27):31-33. PubMed ID: 35080304 [TBL] [Abstract][Full Text] [Related]